More China Woes For GSK? CFDA Wades Into Ozanezumab Controversy
This article was originally published in PharmAsia News
Taking heat from critics amid a report that GSK may have conducted unethical trials for multiple sclerosis drug ozanezumab, China’s Center for Drug Evaluation conducts its own investigation.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
As China is poised to supply medical products to fight the coronavirus around the world, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.